Literature DB >> 21157437

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Maria R Parkhurst1, James C Yang, Russell C Langan, Mark E Dudley, Debbie-Ann N Nathan, Steven A Feldman, Jeremy L Davis, Richard A Morgan, Maria J Merino, Richard M Sherry, Marybeth S Hughes, Udai S Kammula, Giao Q Phan, Ramona M Lim, Stephen A Wank, Nicholas P Restifo, Paul F Robbins, Carolyn M Laurencot, Steven A Rosenberg.   

Abstract

Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against human carcinoembryonic antigen (CEA) were administered to three patients with metastatic colorectal cancer refractory to standard treatments. All patients experienced profound decreases in serum CEA levels (74-99%), and one patient had an objective regression of cancer metastatic to the lung and liver. However, a severe transient inflammatory colitis that represented a dose limiting toxicity was induced in all three patients. This report represents the first example of objective regression of metastatic colorectal cancer mediated by adoptive T cell transfer and illustrates the successful use of a TCR, raised in human leukocyte antigen (HLA) transgenic mice, against a human tumor associated antigen. It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21157437      PMCID: PMC3048186          DOI: 10.1038/mt.2010.272

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  32 in total

1.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Authors:  Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 2.  Toll-like receptors in tumor immunotherapy.

Authors:  Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas C Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

3.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Authors:  Mark E Dudley; James C Yang; Richard Sherry; Marybeth S Hughes; Richard Royal; Udai Kammula; Paul F Robbins; JianPing Huang; Deborah E Citrin; Susan F Leitman; John Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen Morton; Carolyn Laurencot; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.

Authors:  Cyrille J Cohen; Yangbing Zhao; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

5.  A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.

Authors:  Stephen Shibata; Andrew Raubitschek; Lucille Leong; Marianna Koczywas; Lawrence Williams; Jiping Zhan; Jeffrey Y C Wong
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

Authors:  Paul F Robbins; Yong F Li; Mona El-Gamil; Yangbing Zhao; Jennifer A Wargo; Zhili Zheng; Hui Xu; Richard A Morgan; Steven A Feldman; Laura A Johnson; Alan D Bennett; Steven M Dunn; Tara M Mahon; Bent K Jakobsen; Steven A Rosenberg
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

7.  Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.

Authors:  Rinke Bos; Suzanne van Duikeren; Hans Morreau; Kees Franken; Ton N M Schumacher; John B Haanen; Sjoerd H van der Burg; Cornelis J M Melief; Rienk Offringa
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.

Authors:  Herbert J Zeh; Charles K Brown; Matthew P Holtzman; Merrill J Egorin; Julianne L Holleran; Douglas M Potter; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2008-11-25       Impact factor: 5.344

Review 9.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

10.  Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.

Authors:  Maria R Parkhurst; Jayne Joo; John P Riley; Zhiya Yu; Yong Li; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

View more
  391 in total

Review 1.  Raising the bar: the curative potential of human cancer immunotherapy.

Authors:  Steven A Rosenberg
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

2.  Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.

Authors:  Patrick Ho; Christopher Ede; Yvonne Y Chen
Journal:  ACS Synth Biol       Date:  2017-05-22       Impact factor: 5.110

Review 3.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 4.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

Review 6.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

7.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Authors:  Cyrille J Cohen; Jared J Gartner; Miryam Horovitz-Fried; Katerina Shamalov; Kasia Trebska-McGowan; Valery V Bliskovsky; Maria R Parkhurst; Chen Ankri; Todd D Prickett; Jessica S Crystal; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

Review 8.  The emerging role of immunotherapy in colorectal cancer.

Authors:  David Lynch; Adrian Murphy
Journal:  Ann Transl Med       Date:  2016-08

Review 9.  Emerging Systemic Therapies for Colorectal Cancer.

Authors:  Christine M Veenstra; John C Krauss
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

10.  Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Authors:  Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.